Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update
The advent of FVIII-mimetic bispecific antibodies marks a shift in hemophilia A prophylaxis away from FVIII replacement therapies. Next-generation agents may offer enhanced activity and safety. Despite advances, challenges remain in monitoring activity, managing breakthrough bleeds, and understanding non-hemostatic FVIII roles. As long-acting, subcutaneous agents mature, they may redefine care, enabling personalized, safer, and more accessible prophylaxis across the lifespan.
Authors
- Roberto Lúcio Muniz Júnior (ORCID: https://orcid.org/0000-0002-9226-6521)
- Ricardo Mesquita Camelo (ORCID: https://orcid.org/0000-0001-9025-0289)
- Glenn F. Pierce (ORCID: https://orcid.org/0000-0002-3310-328X)
- Douglas Lamounier de Almeida (ORCID: https://orcid.org/0000-0001-6632-7311)
- Vitória Eduarda Alves de Jesus
- Juliana ÁLVARES-TEODORO
Institutions
- Universidade Federal de Minas Gerais (BR)
- Hemophilia Federation of America (US)
- Faculdade de Ciências Médicas de Minas Gerais (BR)
Publication Details
- Journal
- Expert Review of Clinical Pharmacology
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1080/17512433.2026.2636123
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00